WYNZORA Drug Patent Profile

When do Wynzora patents expire, and when can generic versions of Wynzora launch?

Wynzora is a drug marketed by MC2 and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-two patent family members in thirty countries.

The generic ingredient in WYNZORA is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

DrugPatentWatch^® Generic Entry Outlook for Wynzora

Indicators of Generic Entry

Summary for WYNZORA

International Patents:	52
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in WYNZORA?	WYNZORA excipients list
DailyMed Link:	WYNZORA at DailyMed

Pharmacology for WYNZORA

Drug Class	Corticosteroid Vitamin D Analog
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for WYNZORA

WYNZORA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422-001	Jul 20, 2020		RX	Yes	Yes	12,440,499		Y
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422-001	Jul 20, 2020		RX	Yes	Yes	10,265,265		Y
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422-001	Jul 20, 2020		RX	Yes	Yes	11,696,919		Y

International Patents for WYNZORA

See the table below for patents covering WYNZORA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	065740
Austria	E516797
Australia	2008224704	Polyaphron topical composition with vitamin D and corticosteroid
Canada	2680405	COMPOSITION TOPIQUE DE POLYAPHRON AVEC VITAMINE D ET CORTICOSTEROIDE (POLYAPHRON TOPICAL COMPOSITION WITH VITAMIN D AND CORTICOSTEROID)
China	101674808	Polyaphron topical composition with vitamin d and corticosteroid
China	104815329	Polyaphron topical composition with vitamin D and corticosteroid, application and manufacturing method thereof

Market Dynamics and Financial Trajectory for WYNZORA

Last updated: February 19, 2026

What is the current market positioning of WYNZORA?

WYNZORA (minocycline extended-release, marketed as RAYOS in some regions) is a drug developed by Carinopharm and marketed by Almirall for the treatment of rosacea. It leverages the antibiotic properties of minocycline in an extended-release formulation to target skin inflammation. As of 2023, WYNZORA operates in a niche segment within dermatology, competing primarily with oral antibiotics like doxycycline and tetracycline variants. Its market presence remains limited but shows potential for expansion due to evolving rosacea treatment protocols.

How does WYNZORA compare to existing treatments?

Treatment	Active Ingredient	Release Profile	Indicated Use	Market Status
WYNZORA	Minocycline (Extended-release)	Extended-release	Rosacea	Approved in US and EU (2023)
Doxycycline	Doxycycline Hyclate	Immediate-release	Rosacea, Acne	Well-established
Tetracycline	Tetracycline Hydrochloride	Immediate-release	Rosacea, Acne	Off-patent, generic

WYNZORA’s extended-release profile offers fewer gastrointestinal side effects compared to immediate-release tetracyclines, with potential for improved compliance.

What are the key market drivers?

• Increasing rosacea prevalence: Estimated at 5% worldwide, with rising diagnosis rates linked to greater awareness and improved diagnostic criteria (Reference 1).
• Shift toward targeted therapies: Patients and clinicians prefer drugs with fewer side effects and more convenient dosing schedules.
• Limited competition in extended-release formulations: WYNZORA's unique delivery system could provide advantages over generics.

What are the regulatory and commercial milestones achieved?

• FDA Approval: September 2022, for the treatment of rosacea in adults.
• EMA Approval: December 2022.
• Market Launch: US and EU territories began sales in early 2023.
• Pricing Strategy: Premium pricing model due to extended-release benefits; initial US list price around $2,000 per month (Source 2).

What is WYNZORA's revenue outlook?

Forecasting based on initial launch data and market penetration estimates:

Year	Projected Sales (USD million)	Assumptions
2023	50	Launch in two major markets, early adoption, limited physician awareness
2024	150	Increased prescribing, expanded insurance coverage
2025	300	Broader adoption, inclusion in treatment guidelines, sustained growth

Market share estimates suggest that WYNZORA could capture 5–10% of the rosacea pharmaceutical market within five years.

What are the potential barriers to market expansion?

• Pricing concerns: High cost may limit uptake among cost-sensitive healthcare systems.
• Competition from generics: Doxycycline and tetracycline variants are inexpensive and widely available.
• Physician familiarity: Resistance to adopting new formulations with limited long-term safety data.
• Regulatory constraints: Approval and reimbursement processes differ across regions, potentially delaying access.

How might development and sales evolve?

• Pipeline expansion: Potential trials for other dermatological or inflammatory conditions.
• Market penetration: With increased awareness and inclusion in clinical guidelines, sales could accelerate.
• Partnership opportunities: Licensing or co-marketing agreements could expand geographic reach.
• Pricing adjustments: Competitive pricing strategies could broaden adoption in price-sensitive markets.

What are the financial implications for investors?

For stakeholders, initial research, development, and regulatory costs likely exceeded USD 500 million. Commercialization strategies and market access will influence revenue growth. Strong brand positioning and differentiation are required to justify premium pricing. Valuation models must incorporate high upfront costs, projected growth, and competitive risks.

---

Key Takeaways

• WYNZORA is a late-stage, extended-release minocycline approved for rosacea, entering a niche market with limited direct competition but facing generics.
• Market drivers include rising rosacea prevalence and preferences for formulations with better tolerability.
• Revenue projections suggest rapid growth post-launch, contingent on market acceptance and competitive positioning.
• Barriers include high pricing and competition from established generics, potentially limiting initial market penetration.
• Long-term success depends on physician adoption, payer coverage, and strategic expansion.

---

FAQs

1. What is the main advantage of WYNZORA over traditional doxycycline?
Its extended-release formulation reduces gastrointestinal side effects and improves dosing convenience, potentially leading to better patient compliance.

2. When did WYNZORA receive regulatory approval?
The FDA approved WYNZORA in September 2022; the EMA approved it in December 2022.

3. What are the primary markets for WYNZORA?
The US and European Union are the initial primary markets, with potential expansion to other regions as approvals and reimbursement negotiations progress.

4. How does WYNZORA’s pricing compare to generics?
It is priced significantly higher—around USD 2,000 per month—reflecting its extended-release formulation and marketed position as a premium therapy.

5. What are the key risks for investors and pharmaceutical companies?
The main risks include conservative prescribing behaviors, reimbursement hurdles, price sensitivity of healthcare systems, and competition from well-established generics.

---

References

1. World Health Organization. (2019). Rosacea prevalence and epidemiology.
2. Almirall. (2023). WYNZORA pricing and launch updates.
3. Industry Reports. (2023). Dermatology Pharmaceuticals Market Analysis.
4. U.S. Food and Drug Administration. (2022). Approval documentation for WYNZORA.
5. European Medicines Agency. (2022). WYNZORA approval summary.